SEPTIN9 and prostate carcinoma: Some epigenetic biomarkers, such as hypermethylated fragments of SEPT9 in plasma for colorectal cancer diagnosis (sensitivity 90%, specificity 88%, reference [205]) and APC, GSTP1 and RARB2 promoter hypermethylation in urine for prostate cancer detection (sensitivity 69%, specificity 82%, reference [206]) have shown promise for disease diagnosis.